TMCnet News

SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit
[May 24, 2023]

SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology Innovation Summit

STAMFORD, Conn., May 24, 2023 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the virtual TD Cowen 4th Annual Oncology Innovation Summit on Wednesday, May 31, 2023 beginning at 1:00 p.m. ET.

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the company’s website at A replay of the webcast will be available on SpringWorks’ website for a limited time following the event.

About SpringWorks Therapeutics
SpringWorks is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercilizing life-changing medicines for patients living with severe rare diseases and cancer. SpringWorks has a differentiated targeted oncology pipeline spanning solid tumors and hematological cancers, including two late-stage clinical trials in rare tumor types as well as several programs addressing highly prevalent, genetically defined cancers. SpringWorks’ strategic approach and operational excellence in clinical development have enabled it to rapidly advance its two lead product candidates into late-stage clinical trials while simultaneously entering into multiple shared-value partnerships with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients with cancer. For more information, visit and follow @SpringWorksTx on Twitter and LinkedIn.

SpringWorks Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: [email protected]

Samantha Hilson Sandler
Senior Director, Investor Relations
Phone: 203-461-5501
Email: [email protected]

Primary Logo

[ Back To's Homepage ]